Use of cannabidiol for off-label treatment of patients with refractory focal, genetic generalised and other epilepsies

Use of cannabidiol for off-label treatment of patients with refractory focal, genetic generalised and other epilepsies

Abstract Background In randomized controlled trials, add-on cannabidiol (CBD) has been shown to reduce seizure frequency in patients with Lennox-Gastaut syndrome, Dravet syndrome and Tuberous sclerosis complex. Real-world studies provide insights into the drug’s profile in other off-label indication...

Full description

Saved in:
Bibliographic Details
Main Authors: Marie Hollander, Thomas Mayer, Kerstin Alexandra Klotz, Susanne Knake, Felix von Podewils, Gerhard Kurlemann, Ilka Immisch, Felix Rosenow, Susanne Schubert-Bast, Adam Strzelczyk
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Neurological Research and Practice
Online Access:https://doi.org/10.1186/s42466-025-00408-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items